🟢 Tiziana Life Sciences is trading 13% up today after reporting positive Phase 2 PET imaging results for intranasal foralumab in Multiple System Atrophy

Tiziana Life Sciences is trading 13% up at $1.10 today. The surge follows the company's announcement of positive quantitative PET imaging results from the third Multiple System Atrophy (MSA) patient treated with intranasal foralumab. The data showed significant reductions in brain inflammatory activity, with up to 34% reduction in SUV and 26% reduction in SUVR in disease-relevant regions.